Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Aug 4, 2023

Keywords

ClinConnect Summary

The CHAP2 Pilot Project is a clinical trial aimed at studying how treating high blood pressure during pregnancy may affect the health of both mothers and their babies. Specifically, this study focuses on pregnant women who have stage 1 hypertension, which means their blood pressure is slightly elevated (between 130-139/80-89 mmHg). The main goal is to see if lowering blood pressure to less than 130/80 mmHg can lead to better birthweight outcomes for babies. Participants in the study will be divided into two groups: one group will receive treatment to lower their blood pressure, while the other will receive standard care, which only treats high blood pressure when it reaches a higher level.

To be eligible for this trial, women must be expecting a single baby, without any serious fetal issues, and have their blood pressure in the specified range. They should also plan to give birth at UAB Hospital and be receiving care at UAB prenatal clinics. In total, 74 women will be recruited for this study, with half getting active treatment and the other half getting usual care. Participants can expect regular monitoring and support throughout the study. This trial is important because it may help improve how we manage high blood pressure during pregnancy, potentially leading to healthier outcomes for both mothers and their babies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Viable singleton gestation
• • No fetal anomalies
• • Blood pressures 130-139/80-89mmHg on two occasions at least 4 hours apart prior to 20 weeks gestation
• • Planning to deliver at UAB Hospital
• • No indication for pregnancy termination
• • Receiving care at the UAB prenatal clinics
• Exclusion Criteria:
• • Declines Randomization
• • Known diagnosis of chronic hypertension ( BP ≥ 140/90mmHg) or current antihypertensive medication use
• • Fetal demise diagnosed prior to enrollment
• • Known major structural of chromosomal abnormalities prior to enrollment
• • Contraindication to first line antihypertensive (Nifedipine/ Labetalol)
• • Comorbidities requiring BP goals \< 130/80mmHg